Paysign, Inc. (NASDAQ:PAYS – Get Free Report) EVP Joan Herman sold 30,000 shares of the business’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $9.30, for a total transaction of $279,000.00. Following the completion of the sale, the executive vice president directly owned 579,421 shares of the company’s stock, valued at $5,388,615.30. This represents a 4.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Paysign Trading Up 2.8%
Shares of NASDAQ:PAYS traded up $0.27 on Tuesday, reaching $9.81. 1,643,783 shares of the company’s stock were exchanged, compared to its average volume of 1,283,349. The company has a fifty day moving average of $13.50 and a 200-day moving average of $8.76. Paysign, Inc. has a twelve month low of $3.08 and a twelve month high of $16.15. The company has a market capitalization of $557.70 million, a price-to-earnings ratio of 28.91 and a beta of 0.92.
Paysign (NASDAQ:PAYS – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Paysign had a net margin of 18.48% and a return on equity of 35.29%. The company had revenue of $30.80 million for the quarter, compared to analysts’ expectations of $29.02 million. As a group, equities research analysts forecast that Paysign, Inc. will post 0.62 EPS for the current fiscal year.
Wall Street Analyst Weigh In
PAYS has been the topic of a number of analyst reports. Weiss Ratings downgraded Paysign from a “buy (b)” rating to a “buy (b-)” rating in a research report on Monday. Maxim Group cut Paysign from a “buy” rating to a “hold” rating in a report on Wednesday, November 11th. Wall Street Zen cut Paysign from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 16th. Barrington Research set a $15.00 target price on Paysign in a research report on Tuesday, August 11th. Finally, DA Davidson reduced their target price on Paysign from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, November 11th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Paysign currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.81.
Check Out Our Latest Stock Analysis on Paysign
Hedge Funds Weigh In On Paysign
Several hedge funds have recently bought and sold shares of PAYS. Allworth Financial LP raised its position in shares of Paysign by 456.1% in the 3rd quarter. Allworth Financial LP now owns 3,042 shares of the company’s stock valued at $41,000 after buying an additional 2,495 shares in the last quarter. Ausdal Financial Partners Inc. bought a new stake in shares of Paysign during the 3rd quarter worth approximately $177,000. Cetera Investment Advisers boosted its position in shares of Paysign by 21.4% during the 3rd quarter. Cetera Investment Advisers now owns 17,879 shares of the company’s stock worth $241,000 after acquiring an additional 3,146 shares in the last quarter. Entropy Technologies LP acquired a new stake in shares of Paysign during the 3rd quarter worth approximately $337,000. Finally, Caxton Associates LLP acquired a new stake in shares of Paysign during the 3rd quarter worth approximately $257,000. 25.89% of the stock is owned by institutional investors.
About Paysign
Paysign, Inc. provides prepaid card programs, payment processing and related financial technology services. Its platform supports organizations that need to distribute funds and manage payments, including businesses in the healthcare sector. The company serves plasma collection centers with donor compensation and payment solutions, and works with pharmaceutical companies on patient assistance and affordability programs. Its services also support payments for clinical trials and other disbursement needs.
Read More
- Five stocks we like better than Paysign
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.
